Overview
- 4 public-safe observations are available for this inspection.
- 4 structured CFR citations are represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
21 Nov 2014
21 CFR 211.22(a)
Contract drug products--lack of responsibility
Cited by John P Mistler, Mary-Jeanet Mcgarry
21 Nov 2014
21 CFR 314.81(b)(1)(ii)
Contamination, chemical or physical change, deterioration
Cited by John P Mistler, Mary-Jeanet Mcgarry
21 Nov 2014
21 CFR 600.14(a)(1)
Who must report - manufacturer
Cited by John P Mistler, Mary-Jeanet Mcgarry
21 Nov 2014
21 CFR 606.171
Biological product deviation report
Cited by John P Mistler, Mary-Jeanet Mcgarry
Inspected site
GCGenzyme CorporationFramingham, United States
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.22(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 314.81(b)(1)(ii) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 600.14(a)(1) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 606.171 | Cited across public-safe Form 483 observations | 1x |
Full 483 report
Get the verbatim text of all 4 observations
Every observation in full, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere